In January 2018, an update was sent to healthcare professionals about press release from MHRA).
and a risk of inhalation/ingestion of tip cap of prefilled plastic syringes (see
Pharmacists are encouraged to proactively communicate the
included in this letter to parents and caregivers (and patients if appropriate) who have been dispensed Buccolam and who have not already been made aware. Further supplies of Buccolam will contain these instructions, which are to be provided with every pack dispensed.
In addition, in January 2018 the following letters were sent to relevant healthcare professionals:
Misoprostol vaginal delivery system (Mysodelle):
Noradrenaline (Norepinephrine) 0.08 mg/mL (4 mg in 50 mL) solution for infusion in a vial:
Relenza (zanamivir): supply of Taiwanese stock;
Mycophenolate mofetil (MMF)/mycophenolic acid (MPA):
We are also aware of the following two letters, sent to relevant healthcare professionals in December 2017:
Article citation: Drug Safety Update volume 11 issue 7; February 2018: 4.
Published 6 February 2018